Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment

PLoS Pathog. 2016 Jun 15;12(6):e1005687. doi: 10.1371/journal.ppat.1005687. eCollection 2016 Jun.

Abstract

B-cells not only produce immunoglobulins and present antigens to T-cells, but also additional key roles in the immune system. Current knowledge on the role of B-cells in infections caused by intracellular bacteria is fragmentary and contradictory. We therefore analysed the phenotypical and functional properties of B-cells during infection and disease caused by Mycobacterium tuberculosis (Mtb), the bacillus causing tuberculosis (TB), and included individuals with latent TB infection (LTBI), active TB, individuals treated successfully for TB, and healthy controls. Patients with active or treated TB disease had an increased proportion of antibodies reactive with mycobacteria. Patients with active TB had reduced circulating B-cell frequencies, whereas only minor increases in B-cells were detected in the lungs of individuals deceased from TB. Both active TB patients and individuals with LTBI had increased relative fractions of B-cells with an atypical phenotype. Importantly, these B-cells displayed impaired proliferation, immunoglobulin- and cytokine- production. These defects disappeared upon successful treatment. Moreover, T-cell activity was strongest in individuals successfully treated for TB, compared to active TB patients and LTBI subjects, and was dependent on the presence of functionally competent B-cells as shown by cellular depletion experiments. Thus, our results reveal that general B-cell function is impaired during active TB and LTBI, and that this B-cell dysfunction compromises cellular host immunity during Mtb infection. These new insights may provide novel strategies for correcting Mtb infection-induced immune dysfunction towards restored protective immunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes / immunology*
  • Enzyme-Linked Immunosorbent Assay
  • Flow Cytometry
  • Humans
  • Immunohistochemistry
  • Latent Tuberculosis / immunology
  • Mycobacterium tuberculosis / immunology
  • Phenotype
  • Tuberculosis / drug therapy*
  • Tuberculosis / immunology*

Grants and funding

The study was supported by grants from the European Union: EC FP7 IDEA (HEALTH-F3-2009-241642) and TBVAC2020 Horizon2020 (contract no. 643381) as well as EC FP7 ADITEC (contract no. 280873) (the text represents the authors' views and does not necessarily represent a position of the Commission who will not be liable for the use made of such information). Additional funding was obtained from the Italian Ministry of Health “Ricerca Corrente” and RF-2011-02349394. HHS was supported by a VIDI grant from the Dutch Organization for Scientific Research (ZonMW-VIDI -016.146.352). The funders had no role in the decision to publish the study, in analyzing the data or drafting the manuscript.